Our top pick for
Kura Oncology, Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 71 staff and has a market cap (total outstanding shares value) of USD$1.9 billion.
|52-week range||USD$6.35 - USD$35.25|
|50-day moving average||USD$29.5823|
|200-day moving average||USD$19.7796|
|Wall St. target price||USD$30.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.568|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-15.76%|
|Return on equity TTM||-26%|
|Market capitalisation||USD$1.9 billion|
TTM: trailing 12 months
There are currently 3.0 million Kura Oncology shares held short by investors – that's known as Kura Oncology's "short interest". This figure is 22.6% down from 3.9 million last month.
There are a few different ways that this level of interest in shorting Kura Oncology shares can be evaluated.
Kura Oncology's "short interest ratio" (SIR) is the quantity of Kura Oncology shares currently shorted divided by the average quantity of Kura Oncology shares traded daily (recently around 772082.73195876). Kura Oncology's SIR currently stands at 3.88. In other words for every 100,000 Kura Oncology shares traded daily on the market, roughly 3880 shares are currently held short.
However Kura Oncology's short interest can also be evaluated against the total number of Kura Oncology shares, or, against the total number of tradable Kura Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kura Oncology's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Kura Oncology shares in existence, roughly 50 shares are currently held short) or 0.0636% of the tradable shares (for every 100,000 tradable Kura Oncology shares, roughly 64 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kura Oncology.
Find out more about how you can short Kura Oncology stock.
We're not expecting Kura Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $6.35 up to $35.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 2.2885. This would suggest that Kura Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.